Bb Biotech AG 13F Holdings · last filed Q1 2019
Bb Biotech AG reported 35 securities worth $3.98B in its SEC 13F filing for Q1 2019 (period ended 2019-03-31). Top holdings: IONS (15.76%), INCY (7.83%), NBIX (7.46%). Among its top 25 positions this quarter: 11 added, 6 trimmed.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | IONS | Ionis Pharmaceuticals Inc. | $627.0M | 15.76% | 7.7M | Trimmed |
| 2 | INCY | Incyte Corp. | $311.4M | 7.83% | 3.6M | Trimmed |
| 3 | NBIX | Neurocrine Biosciences Inc. | $296.6M | 7.46% | 3.4M | Added |
| 4 | VRTX | Vertex Pharmaceuticals Inc | $239.1M | 6.01% | 1.3M | Trimmed |
| 5 | SAGE | Sage Therapeutics, Inc. | $218.7M | 5.50% | 1.4M | Hold |
| 6 | CELG | Celgene Corp | $207.5M | 5.22% | 2.2M | Trimmed |
| 7 | AGIO | Agios Pharmaceuticals, Inc. | $200.8M | 5.05% | 3.0M | Added |
| 8 | ALXN | Alexion Pharmaceuticals, Inc. | $177.7M | 4.47% | 1.3M | Hold |
| 9 | ALNY | Alnylam Pharmaceuticals, Inc. | $152.4M | 3.83% | 1.6M | Added |
| 10 | ESPR | Esperion Therapeutics, Inc. | $141.4M | 3.56% | 3.5M | Added |
| 11 | RDUS1 | Radius Health, Inc. | $135.2M | 3.40% | 6.8M | Added |
| 12 | HALO | Halozyme Therapeutics Inc. | $134.0M | 3.37% | 8.3M | Hold |
| 13 | ARGX | Argenx SE | $112.9M | 2.84% | 904,739 | Added |
| 14 | MRNA | Moderna, Inc. | $97.4M | 2.45% | 4.8M | Hold |
| 15 | MYOV | Myovant Sciences Ltd. | $85.9M | 2.16% | 3.6M | Hold |
| 16 | ICPT | Intercept Pharmaceuticals, Inc. | $78.0M | 1.96% | 696,976 | Added |
| 17 | GILD | Gilead Sciences Inc. | $74.3M | 1.87% | 1.1M | Trimmed |
| 18 | NKTR | Nektar Therapeutics | $67.9M | 1.71% | 2.0M | Added |
| 19 | EXEL | Exelixis, Inc. | $67.5M | 1.70% | 2.8M | Hold |
| 20 | AKCA | Akcea Therapeutics, Inc. | $67.4M | 1.69% | 2.4M | Trimmed |
| 21 | MYOK | Myokardia Inc. | $65.8M | 1.65% | 1.3M | Added |
| 22 | MGNX | MacroGenics Inc. | $61.1M | 1.54% | 3.4M | Added |
| 23 | WVE | Wave Life Sciences Ltd. | $56.9M | 1.43% | 1.5M | Hold |
| 24 | VYGR | Voyager Therapeutics, Inc. | $54.9M | 1.38% | 2.9M | Hold |
| 25 | BOLD1 | Audentes Therapeutics, Inc. | $53.4M | 1.34% | 1.4M | Added |
Source: SEC Form 13F filings · as of 2019-03-31
Every position in this 13F-HR, with its change from the prior quarter.
13F holdings, latest quarter
SourceSEC EDGAR13F-HR